Toyota|$18.02 (¥2,881)+1.30%▲ (in JPY terms)
Sony|$22.64 (¥3,619)-1.36%▼ (in JPY terms)
SoftBank|$52.01 (¥8,315)-3.67%▼ (in JPY terms)
MUFG|$19.62 (¥3,137)+2.99%▲ (in JPY terms)
Keyence|$504.36 (¥80,630)+2.92%▲ (in JPY terms)
Nintendo|$46.65 (¥7,457)+0.42%▲ (in JPY terms)
NTT|$0.92 (¥148)-0.07%▼ (in JPY terms)
Takeda|$29.70 (¥4,748)-2.10%▼ (in JPY terms)
Tokyo Electron|$380.94 (¥60,900)+13.39%▲ (in JPY terms)
Recruit|$68.31 (¥10,920)+0.69%▲ (in JPY terms)
ITOCHU|$11.63 (¥1,859)+0.05%▲ (in JPY terms)
Honda|$9.36 (¥1,497)+7.89%▲ (in JPY terms)
Shin-Etsu|$48.83 (¥7,806)+4.46%▲ (in JPY terms)
Tokio Marine|$44.40 (¥7,098)+0.74%▲ (in JPY terms)
Fast Retailing|$490.54 (¥78,420)-1.58%▼ (in JPY terms)
Toyota|$18.02 (¥2,881)+1.30%▲ (in JPY terms)
Sony|$22.64 (¥3,619)-1.36%▼ (in JPY terms)
SoftBank|$52.01 (¥8,315)-3.67%▼ (in JPY terms)
MUFG|$19.62 (¥3,137)+2.99%▲ (in JPY terms)
Keyence|$504.36 (¥80,630)+2.92%▲ (in JPY terms)
Nintendo|$46.65 (¥7,457)+0.42%▲ (in JPY terms)
NTT|$0.92 (¥148)-0.07%▼ (in JPY terms)
Takeda|$29.70 (¥4,748)-2.10%▼ (in JPY terms)
Tokyo Electron|$380.94 (¥60,900)+13.39%▲ (in JPY terms)
Recruit|$68.31 (¥10,920)+0.69%▲ (in JPY terms)
ITOCHU|$11.63 (¥1,859)+0.05%▲ (in JPY terms)
Honda|$9.36 (¥1,497)+7.89%▲ (in JPY terms)
Shin-Etsu|$48.83 (¥7,806)+4.46%▲ (in JPY terms)
Tokio Marine|$44.40 (¥7,098)+0.74%▲ (in JPY terms)
Fast Retailing|$490.54 (¥78,420)-1.58%▼ (in JPY terms)

2026-05-08 FUJIFILM Holdings Corporation “Fujifilm has obtained manufacturing and marketing approval for "Seibicus® Injection," the first regenerative medicine product in Japan for treating meniscus injuries.”

by

2026-05-08 FUJIFILM Holdings Corporation “Fujifilm has obtained manufacturing and marketing approval for "Seibicus® Injection," the first regenerative medicine product in Japan for treating meniscus injuries.”

AI-Generated Summary

Fujifilm has secured regulatory approval for its first regenerative medicine product in Japan, potentially opening a new revenue stream in the growing cell therapy market and demonstrating successful execution of its healthcare strategy. This approval strengthens Fujifilm’s competitive position in regenerative medicine and could support future growth in its pharmaceuticals and medical devices segment.

This summary is AI-generated based on the release title and may not reflect the full content of the original document.

Tags: FUJIFILM Holdings CorporationJP3814000000

コメントする

Contact